Abstract Background. The US Food and Drug Administration (FDA) and European
Medicines Agency (EMA) have approved updated dose recommendations for intravenous …

Background. Intravenous colistin is difficult to use because plasma concentrations for
antibacterial effect overlap those causing nephrotoxicity, and there is large interpatient …

With increasing clinical emergence of multidrug-resistant Gram-negative pathogens and the
paucity of new agents to combat these infections, colistin (administered as its inactive …

Background: Presently, colistin is commercially available in two different forms, namely,
colistin sulfate and its sulphomethylated derivative, colistimethate sodium (CMS). However …

Colistin is an old antibiotic that has recently gained a considerable renewal of interest as the
last-line defense therapy against multidrug-resistant Gram-negative bacteria. It is …

Background Optimizing colistin dosing should translate to improved patient outcomes.
Methods We used data from 2 prospective cohort studies performed between 2006 and …

Background The intravenous use of polymyxins has been considered to be associated with
considerable nephrotoxicity and neurotoxicity. For this reason, the systemic administration of …

Background: The emergence of multidrug-resistant nosocomial pathogens, such as
Pseudomonas aeruginosa and Acinetobacter baumannii, has led to the revival of the …

Nephrotoxicity limits the effective use of colistin for the treatment of multidrug-resistant Gram-
negative bacteria (MDR-GNB) infections. We previously defined a steady-state colistin …

Background Infections caused by multidrug-resistant gram-negative bacteria have caused a
resurgence of interest in colistin. To date, information about pharmacokinetics of colistin is …